Felder Christian C, Dickason-Chesterfield Amy K, Moore Steven A
Eli Lilly and Co., Neuroscience Division, Indianapolis, IN 46285, USA.
Mol Interv. 2006 Jun;6(3):149-61. doi: 10.1124/mi.6.3.6.
Cannabinoids, in the form of marijuana plant extracts, have been used for thousands of years for a wide variety of medical conditions, ranging from general malaise and mood disorders to more specific ailments, such as pain, nausea, and muscle spasms. The discovery of tetrahydrocannabinol, the active principal in marijuana, and the identification and cloning of two cannabinoid receptors (i.e., CB1 and CB2) has subsequently led to biomedical appreciation for a family of endocannabinoid lipid transmitters. The biosynthesis and catabolism of the endocannabinoids and growing knowledge of their broad physiological roles are providing insight into potentially novel therapeutic targets. Compounds directed at one or more of these targets may allow for cannabinoid-based therapeutics with limited side effects and abuse liability.
大麻素，以大麻植物提取物的形式，已经被用于治疗各种医疗状况长达数千年，范围从全身不适和情绪障碍到更具体的疾病，如疼痛、恶心和肌肉痉挛。大麻中的活性成分四氢大麻酚的发现，以及两种大麻素受体（即CB1和CB2）的鉴定和克隆，随后引发了生物医学对一类内源性大麻素脂质递质的重视。内源性大麻素的生物合成和分解代谢，以及对其广泛生理作用的不断了解，正在为潜在的新型治疗靶点提供见解。针对这些靶点中的一个或多个的化合物可能会产生副作用有限且滥用可能性低的基于大麻素的疗法。
